Screener
Taysha Gene Therapies, Inc. TSHA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 33,809 | 15,565 |
| General and administrative | 9,677 | 8,158 |
| Total operating expenses | 43,486 | 23,723 |
| Loss from operations | (43,486) | (21,421) |
| Other (expense) income: | ||
| Change in fair value of warrant liability | — | 102 |
| Change in fair value of term loan | (1,470) | (1,530) |
| Interest income | 2,586 | 1,326 |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s operating income?
- Taysha Gene Therapies, Inc. (TSHA) reported operating income of -$43.49M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s operating income changed year-over-year?
- Taysha Gene Therapies, Inc.'s operating income decreased by 103.0% year-over-year, from -$21.42M to -$43.49M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s operating income?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s operating income has grown at a -10.6% compound annual growth rate (CAGR), from -$173.27M to -$110.5M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Taysha Gene Therapies, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude